Literature DB >> 22178100

CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes.

Rajesh Singh1, Shailesh Singh, David E Briles, Dennis D Taub, Susan K Hollingshead, James W Lillard.   

Abstract

Understanding the requirements for protection against pneumococcal carriage and pneumonia will greatly benefit efforts in controlling these diseases. Several antigens, in addition to the polysaccharide capsule, have been implicated in both the virulence and protective immunity against Streptococcus pneumoniae; one of the best-studied S. pneumoniae antigens is pneumococcal surface protein A (PspA). Recently, it was shown that genetic polymorphisms could diminish CCL5 expression, which results in increased susceptibility to and progression of infectious diseases. We previously showed CCL5 blockade reduced PspA-specific humoral and cellular pneumococcal immunity, during S. pneumoniae strain EF3030-induced carriage, by diminishing IFN-γ and enhancing IL-10 secretion by effector T cells. We also identified immuno-dominant helper T lymphocyte (HTL) epitopes in PspA peptide 19-23 (PspA(199-246)), which caused comparatively more cytokine secretion and proliferation responses by splenic and cervical lymph node (CLN) CD4(+) T cells from mice previously challenged with S. pneumoniae strain EF3030. In this study, we sought to determine if PspA(199-246)-specific CD4(+) T cells responses were resistant to the effect of CCL5 deficiency. In short, T cell responses against these HTL epitopes were resistant to CCL5 inhibition, than compared to cells from control or naïve mice, and unaffected by reduced co-stimulatory molecule expression caused by CCL5 blockade. CCL5 deficiency also corresponded with a higher number of IL-10(+) CD11b(+) CD11c(Lo) and CD11b(+) CD11c(Hi) cells and lower IFN-γ expression by similar cells, than compared to controls. These data confirm CCL5 is an essential factor for optimal pneumococcal adaptive immunity and show CD4(+) T cell responses to PspA(199-246) are largely resistant to CCL5 deficiency.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178100      PMCID: PMC3269505          DOI: 10.1016/j.vaccine.2011.12.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  48 in total

1.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

2.  Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

Authors:  Sheng Zhang; Rafael Cubas; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Immunol       Date:  2009-04-18       Impact factor: 4.407

3.  Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae.

Authors:  D E Briles; M J Crain; B M Gray; C Forman; J Yother
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

4.  Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis.

Authors:  A Sette; S Buus; E Appella; J A Smith; R Chesnut; C Miles; S M Colon; H M Grey
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

5.  Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae.

Authors:  A M Berry; J Yother; D E Briles; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

6.  Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

Authors:  J Alexander; J Sidney; S Southwood; J Ruppert; C Oseroff; A Maewal; K Snoke; H M Serra; R T Kubo; A Sette
Journal:  Immunity       Date:  1994-12       Impact factor: 31.745

7.  Synthesis of peptide analogues using the multipin peptide synthesis method.

Authors:  R M Valerio; M Benstead; A M Bray; R A Campbell; N J Maeji
Journal:  Anal Biochem       Date:  1991-08-15       Impact factor: 3.365

8.  IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection.

Authors:  Koenraad F van der Sluijs; Leontine J R van Elden; Monique Nijhuis; Rob Schuurman; Jennie M Pater; Sandrine Florquin; Michel Goldman; Henk M Jansen; René Lutter; Tom van der Poll
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

9.  MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity.

Authors:  James W Lillard; Udai P Singh; Prosper N Boyaka; Shailesh Singh; Dennis D Taub; Jerry R McGhee
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

10.  Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).

Authors:  L S McDaniel; J Yother; M Vijayakumar; L McGarry; W R Guild; D E Briles
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

View more
  1 in total

1.  Overexpression of methyl-CpG-binding protein 2 and autoimmunity: evidence from MECP2 duplication syndrome, lupus, MECP2 transgenic and Mecp2 deficient mice.

Authors:  A H Sawalha
Journal:  Lupus       Date:  2013-07-16       Impact factor: 2.911

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.